



American Society for  
Experimental Neurotherapeutics



ASENT 20th Annual Meeting  
**March 7-10, 2018**

Hilton Washington-DC/Rockville Hotel & Executive Meeting Center

**ADVANCE PROGRAM**

# Save the Date

## March 7-10, 2018

### Hilton Rockville



#### IMPORTANT DATES

Early Registration Deadline

► **January 18, 2018**

Abstract Submission Deadline

► **January 29, 2018**

Hotel Reservation Deadline

► **February 12, 2018**

Annual Meeting Dates

► **March 7-10, 2018**

#### TABLE OF CONTENTS

About the Meeting - **Page 3**

Full Program - **Page 4**

Training in Neurotherapeutics  
Course Agenda - **Page 10**

Registration Information - **Page 14**

ASENT Leadership - **Page 18**

### Letter from the President



The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders.

At the ASENT meeting you will connect with hundreds of MDs, MD/PhDs, PhDs, and others from the Neurotherapeutics community including:

- Funders from venture capital firms and strategic investors with a particular interest in neurotherapeutics
- Neurology and Neuroscience faculty from academic institutions
- Professionals from drug development in industry
- Leadership from NIH, NINDS, FDA and other essential government agencies
- Representatives from patient advocacy organizations
- Basic science researchers, clinical researchers, and pharmacy specialists

Our primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system, and we are honored that you would consider attending the ASENT 20th Annual Meeting.

Included you will find details on the outstanding sessions and speakers planned for this meeting. If you have questions on registration, sponsorship opportunities or other meeting related matters please let us know by emailing our Executive Director, Jessica Smith at [jessicasmith.asent@gmail.com](mailto:jessicasmith.asent@gmail.com). She will be happy to have a discussion at a time that is convenient for you.

Marty,

**Martha Morrell, MD**

**Chief Medical Officer, NeuroPace, Inc.**

**Clinical Professor of Neurology, Stanford University**

**President, American Society for Experimental Neurotherapeutics**

# Save the Date

# March 7-10, 2018

## Hilton Rockville



## ASENT

The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders.

## Location

The ASENT annual meeting is held in Rockville, MD at the Hilton Washington DC/ Rockville Hotel & Executive Meeting Center from March 7 - 10, 2018.

## An outstanding experience

### For CNS Clinicians & Scientists

Review innovative scientific research from peers in academia and industry. This meeting is an opportunity to connect with thought-leaders on drugs and devices making their way to market in a wide variety of therapeutic areas.

### For Industry

Connect with advocates, government and practitioners in the field to discuss forthcoming neurotherapeutics.

### For Students and Junior Faculty

Submit your poster at a meeting where you will have it reviewed by a team of experts, and presented to leaders in the field of neurotherapeutics.

## Notable Speakers

You will find CEOs, Chief Medical Officers, Founders, Chairs of Departments, Division Directors and other leaders in the field. A few notable speakers include:

**Michael Okun, MD**, Chair of Neurology and Administrative Director and Co-director of the Center for Movement Disorders and Neurorestoration at the University of Florida; **Carlos Peña, PhD**, Director, Division of Neurological and Physical Medicine Devices (DNPM), FDA; **Warren Lammert**, President, Chief Investment Officer, and Portfolio Manager of Granite Point Capital Master Fund, L.P.; and **E. Ray Dorsey, MD, MBA**, David M. Levy Professor of Neurology and Director of the CHET at the University of Rochester Medical Center.

## Who will be in Rockville, MD?

### Academics

### Basic Researchers

### Chairs of Neurology

### Chairs of Neuroscience

### Chief Medical Officers

### CIOs

### Device Companies

### FDA

### Founders

### Investors

### Medical Students, Residents & Fellows

### Neurology Faculty

### Neuroscience Faculty

### NIH

### NINDS

### Patient Advocates

### Pharmaceutical Companies

### Program Directors

### Research Institutes

### Translational Researchers



## Wednesday, March 7, 2018

TIME	ACTIVITY
7:00 am - 7:30 am	<b>Breakfast</b>
7:45 am - 8:15pm	<p><b>Training in Neurotherapeutics Discovery and Development for Academic Scientists: Day 1</b>  Chairs: Michael Rogawski, MD, PhD, Professor, Neurology, University of California, Davis  Barbara Slusher, PhD, MAS, Professor of Neurology, Psychiatry, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine  Karl Scheidt, Professor, Northwestern Medicine, Founder, Third Coast Therapeutics</p> <p>This training program in neurotherapeutics discovery and development is an intensive 3½ -day course that provides trainees with the knowledge required to discover and advance a neurotherapeutic agent to Investigational New Drug (IND) Application. The course, which is designed to be applicable to diverse diseases of the nervous system, will equip students with a broad understanding of the various component steps in the neurotherapeutics drug discovery and development process. Participants must apply.</p> <p>For details on agenda and faculty see page 11</p>
9:00 am - 3:35 pm	<p><b>PRE-MEETING SYMPOSIUM</b>  <b>ASENT Translational Research Course</b>  Chair: Steven Schachter, MD, Professor, Neurology, Harvard Medical School</p> <p>The goal of this full day course is to focus on healthcare providers and their interactions with industry and government to develop clinical translational research. Currently there is a gap in knowledge regarding the ability to move drugs and devices from bench to bedside including developing appropriate partnerships, understanding intellectual property, trial design and statistics, and regulatory paths and funding opportunities. This course will be a first step in filling those knowledge gaps.</p>
9:00am – 9:10am	<p>Overview</p> <p>Stewart Factor, DO, Professor of Neurology, Director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine</p>
9:10am – 9:35am	<p>Forming and Sustaining Effective Collaborations between Clinicians and Engineers/Scientists</p> <p>Steve Schachter, MD, Professor, Neurology, Harvard Medical School</p>
9:35am – 10:00am	<p>Repurposing Drugs, including Regulatory Aspects</p> <p>Stephen Collins, President and CEO, Biscayne Neurotherapeutics</p>
10:00am – 10:25am	<p>Requirements for Pharmaceuticals and Devices (exclusive of repurposing)</p> <p>Carlos Peña, PhD, Director, Division of Neurological and Physical Medicine Devices (DNPM), FDA</p>
10:25am – 10:50am	Break
10:50am – 11:15am	<p>Identifying Stakeholders in the Healthcare Ecosystem</p> <p>Michael Gold, MD, Vice President, Development Neurosciences, AbbVie</p>
11:15am – 11:40am	<p>SBIR and Other NINDS Funding Opportunities and Resources for Translational Researchers, NIH funding for repurposing drugs</p> <p>Amir Tamiz, PhD, Director, Division, Translational Research, NINDS/NIH</p>
11:40am – 12:30pm	Panel Discussion, overview of afternoon session
12:30pm – 1:50pm	<p><b>LUNCH BREAK</b></p> <p>Lunch and remainder of day with students of <i>Training in Neurotherapeutics Discovery and Development for Academic Scientists</i></p>

## Wednesday, March 7, 2018

TIME	ACTIVITY
TBD	<b>Board Meeting</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.
1:55pm – 2:20pm	<b>ASENT Translational Research Course continued</b> The Innovation Cycle and Defining Clinical Needs  Mike Dempsey, Entrepreneur in Residence and Director of the Accelerator program at the Center for the Integration of Medicine and Innovative Technology (CIMIT)
2:20pm – 2:45pm	Putting Together an Action Plan to Patient: the Healthcare Innovation Impact and Tracking System (HIITS) Metrics  John Collins, PhD, Faculty, CIMIT, Founder and CEO, Secora.Care
2:45pm – 3:35pm	IP Relevant to Neurotherapeutics  Jeffrey Childers, PhD, Partner, Michael Best & Friedrich LLP (formerly Johns Hopkins Technology Transfer)
TBD	<b>Committee Meetings</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.
6:00 pm - 8:30 pm	<b>Careers in Neuroscience Dinner</b> Chair: Martha Morrell, MD Chief Medical Officer, NeuroPace, Inc.  Faculty: TBD

## Thursday, March 8, 2018

TIME	ACTIVITY
7:30 am - 8:30 am	Breakfast
7:30 am - 8:00 am	<b>Welcome Breakfast for New Members</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc. All new members invited to meet the ASENT Board of Directors
7:45 am - 8:30pm	<b>Training in Neurotherapeutics Discovery and Development for Academic Scientists: Day 2</b> Chairs: Michael Rogawski, MD, PhD, Professor, Neurology, University of California, Davis Barbara Slusher, PhD, MAS, Professor of Neurology, Psychiatry, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine Karl Scheidt, Professor, Northwestern Medicine, Founder, Third Coast Therapeutics
8:30 am - 9:00 am	<b>President's Welcome Remarks</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.
9:00 am - 12:00 pm	<b>Pipeline Presentations: Part 1</b> Chair: Kathleen Clarence-Smith, MD, PhD, Co-Founder, Partner, KM Pharmaceuticals  Faculty TBD
12:00 pm - 2:00 pm	<b>Lunch with Pipeline Presenters</b> Chair: Kathleen Clarence-Smith, MD, PhD, Co-Founder, Partner, KM Pharmaceuticals
12:00 pm - 1:00 pm	<b>Advocacy Engagement Committee Meeting</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.
1:00 pm - 2:00 pm	<b>Industry Engagement Committee Meeting</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.
2:00 pm - 3:30 pm	<b>Pipeline Presentations: Part 2</b> Chair: Kathleen Clarence-Smith, MD, PhD, Co-Founder, Partner, KM Pharmaceuticals Faculty TBD
3:30 pm - 3:45 pm	<b>Break</b>

## Thursday, March 8, 2018

TIME	ACTIVITY
3:45 pm - 5:30 pm	<b>Poster Presentations</b> Chair: Kathleen Clarence-Smith, MD, PhD, Co-Founder, Partner, KM Pharmaceuticals
3:45 pm - 5:30 pm	<b>Poster Reception</b>
6:00 pm - 8:30 pm	<b>Dinner Symposium: Patient Involvement in Drug Approval – debate</b> <b>Chair:</b> Robin Elliott, MA, President, Parkinson's Disease Foundation (retired)  <b>Faculty</b> <i>Roger Porter, MD, Consultant</i> <i>Frank J. Sasinowski, MS, MPH, JD, Director, Hyman, Phelps &amp; McNamara, P.C.</i>

## Friday, March 9, 2018

TIME	ACTIVITY
7:00 am - 8:00 am	<b>Breakfast</b>
7:45 am - 8:30 pm	<b>Training in Neurotherapeutics Discovery and Development for Academic Scientists: Day 3</b> Chairs: Michael Rogawski, MD, PhD, Professor, Neurology, University of California, Davis Barbara Slusher, PhD, MAS, Professor of Neurology, Psychiatry, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine Karl Scheidt, Professor, Northwestern Medicine, Founder, Third Coast Therapeutics
8:00 am - 10:00 am	<b>Symposium: Clinical Trials: Lessons Learned: From Patient Recruitment to Innovative Designs</b> Chair: Dietrich Haubenberger, MD, Director, Clinical Trials Unit, NINDS/NIH  <b>Faculty</b> <i><b>Value of subject registries in clinical development</b></i> <i>Stephen Petrouka, MD, PhD, Vice President, Global Therapeutic Area Head - NeurosciencePPD</i>  <i><b>The science of recruitment</b></i> <i>Joshua Grill, PhD, Director Education, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine</i>  <i><b>Best practice &amp; lessons learned applying novel trial designs in industry development programs: What works, what doesn't. (tentative)</b></i> <i>Michael Gold, MD, Vice President, Development Neurosciences, AbbVie</i>  <i><b>Best practice &amp; lessons learned for recruiting into Alzheimer's trials</b></i> <i>Lawrence Friedhoff, MD, PhD, Business Development, Roivant Sciences, Inc.</i>
8:00 am - 10:00 am	<b>Emerging Therapies: ADHD</b> Co-Chair: Enrique Carrazana, MD, Member, Board of Directors, Marinus Pharmaceuticals Co-Chair: Petra Kaufmann, MD, MSc, Director, NCATS Office of Rare Diseases Research  <b>Faculty</b> <i><b>ADHD and risk for substance use disorders: Can neuroimaging guide our understanding?</b></i> <i>Kevin M. Gray, MD, Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina</i>  <i><b>Update on Supernus ADHD Program</b></i> <i>Stefan Schwabe, MD, PhD, Executive Vice President, Head of R&amp;D, Supernus Pharmaceuticals</i>  <i><b>Regulatory perspectives of drug development in psychostimulant abuse</b></i> <i>Beatrix Rocha, Global Regulatory Affairs, Covance</i>  <i><b>Avekshan's abuse deterrent formulation of Methylphenidate</b></i> <i>Pradeep Bhide, PhD, Rodgers Eminent Scholar Chair of Developmental Neuroscience, Florida State University and Co-Founder, Avekshan, LLC</i>  <i><b>Development of novel COMT inhibitors for the treatment of ADHD</b></i> <i>Gregory V. Carr, PhD, Investigator, Lieber Institute for Brain Development</i>  <i><b>The development of brain penetrant COMT-inhibitors for treatment of ADHD</b></i> <i>Ron Marcus, MD, Consultant, Cerecor</i>
10:00 am - 10:15 am	Break

TIME	ACTIVITY
10:15 am - 12:15 pm	<p><b>Symposium: Technological Innovations in Clinical Trials Research and Neurotherapeutic Development</b>            Co-Chair: Robert W. Hamill, MD, Professor, Neurological Sciences, Emeritus, University of Vermont            Co-Chair: E. Ray Dorsey, MD, MBA, David M. Levy Professor of Neurology &amp; Director, Center for Health + Technology, University of Rochester</p> <p><b>Faculty</b>  <i>Evolution of neurology clinical trials including digital biomarkers</i>            E. Ray Dorsey, MD, MBA, David M. Levy Professor of Neurology &amp; Director, Center for Health + Technology, University of Rochester</p> <p><i>How evolving technologies including social media facilitate recruitment, retention, and trial conduct and outcomes</i>            Erika Augustine, MD, Child Neurologist, University of Rochester</p> <p><i>Technology derived novel endpoints: Lessons from CTTI (Clinical Trials Transformation Initiative)</i>            Daniel Karlin, MD, Head of Clinical Informatics and Regulatory Strategy, Pfizer</p> <p><i>Venture capital and neurotherapeutics: Lessons from Epilepsy</i>            Warren Lammert, Founder and Chief Investment Officer, Granite Point Capital Management, L.P.</p>
10:15 am - 12:15 pm	<p><b>Symposium: Non-Small molecule alternatives to pharmaceuticals for neurology</b>            Chair: C. Anthony Altar, PhD, Chief Scientific Officer and Senior Vice President, Verge Genomics, Inc.</p> <p><b>Faculty</b>  <i>Antisense oligonucleotides for CNS disorders</i>            Toby Ferguson, MD, PhD, Medical Director, Biogen</p> <p><i>Antibodies for CNS disorders</i>            Ronald DeMattos, PhD, Chief Scientific Officer, Neurobiologics, Eli Lilly and Company</p> <p><i>Adeno-associated viruses for CNS disorders: Initial proof of concept for Parkinson's Disease</i>            Steven Paul, MD, CEO, Voyager Therapeutics</p> <p><i>Active immunotherapy vaccines for CNS disorders</i>            Ajay Verma, MD, PhD, United Neuroscience</p>
12:15 pm - 1:00 pm	<b>Lunch</b>
1:00 pm - 2:30 pm	<p><b>Emerging Therapies: Alzheimer's Disease</b>            Chair: Korie Handwerger, Science Communications Manager, RA Capital Management, LLC</p> <p><b>Faculty</b>  <i>Designing GAIM fusions to target multiple protein aggregates</i>            Rajaraman Krishnan, PhD, MS, Senior Director Research, Proclara Biosciences</p> <p><i>The clinical development and therapeutic potential of AXS-05 for the neuropsychiatric symptoms of Alzheimer's disease</i>            Harriet Tabuteau, Founder, Chairman, CEO &amp; President, Axsome Therapeutics</p> <p><i>Targeting hippocampal overreactivity in prodromal Alzheimer's disease</i>            Michela Gallagher, Founder and Scientific Advisor, AgeneBio, Kreiger-Eisenhower Professor of Psychological Brain Science, Johns Hopkins, University</p> <p><i>Stimulating protein clearance from the CNS for the treatment of Alzheimer's disease</i>            Phillip Haydon, President, GliaCure, the Annetta and Gustav Grisard Professor and Chair, Department of Neuroscience, Tufts University</p>
1:00 pm - 2:30 pm	<p><b>Symposium: Investing in Neurotherapeutics</b>            Chairs: Robin Elliott, MA, President, Parkinson's Disease Foundation (retired)</p> <p><b>Faculty</b>            TBD</p>

# Friday, March 9, 2018

TIME	ACTIVITY
2:30 pm - 2:45 pm	<b>Break</b>
2:45 pm - 4:15 pm	<p><b>Emerging Therapies: Epilepsy Devices</b> Chair: Steven Schachter, MD, Professor, Neurology, Harvard Medical School</p> <p><b>Faculty</b> <i><b>Silk-based adenosine delivery and gene therapy based focal adenosine augmentation strategies for seizure suppression and antiepileptogenesis</b></i> Traci Plumb, Research Associate, Legacy Research Institute</p> <p><i><b>Empatica. Embrace: Autonomic and seizure events - personalized monitoring and alerts</b></i> Rosalind W. Picard, ScD, Chief Scientist, Empatica, Inc., Co-Founder, Affective Computing Research Group, Professor, Massachusetts Institute of Technology Media Lab</p> <p><i><b>Smart monitor: Automated seizure tracking and recording</b></i> Anoo Nathan, President and CEO, Smart Monitor</p> <p><i><b>Subgaleal EEG recording platform</b></i> Knud Stampe, Marketing Manager, UNEEG medical</p>
2:45 pm - 4:15 pm	<p><b>Emerging Therapies: ALS</b> Chair: C. Anthony Altar, PhD, Chief Scientific Officer and Senior Vice President, Verge Genomics, Inc.</p> <p><b>Faculty</b> <i><b>Nuclear Export inhibitor KPT-350 for ALS</b></i> Sharon Tamir, Director, Strategic Product Development, Head of Neurodegenerative and Infectious Diseases, Karyopharm Therapeutics, Inc.</p> <p><i><b>Genomic-based drug discovery for neurodegenerative diseases</b></i> Alice Zhang, CEO and Co-Founder, Verge Genomics, Inc.</p> <p><i><b>Gene therapy for ALS using plasmid DNA expressing human hepatocyte growth factor</b></i> Marie-Laure Nevoret, MD, Clinical Director, VM BioPharma, ViroMed Co., Ltd.</p> <p><i><b>GM6 – An Endogenous Multiple-Target Regulator Provides a Novel Regulatory Peptide Therapeutic Strategy for Treatment of ALS and Other Neurodegenerative Diseases</b></i> Winston Ko, Chairman and CEO of Genervon Biopharmaceuticals</p>
4:15 pm - 4:30 pm	<b>Break</b>
4:30 pm - 6:00 pm	<p><b>Emerging Therapies: Epilepsy Drugs</b> Chair: Steven Schachter, MD, Professor, Neurology, Harvard Medical School</p> <p><b>Faculty</b> <i><b>ZX008 for the treatment of Dravet Syndrome</b></i> Gail Farfel, PhD, Chief Development Officer, Zogenix</p> <p><i><b>ANAVEX 2-73 as a potential treatment for Rett Syndrome and other pediatric or infantile disorders with seizure pathology</b></i> Christopher Missling, PhD, President and CEO, Anavex Life Sciences Corp</p> <p><i><b>CBD/CBDV</b></i> Ken Sommerville, Vice President, Clinical Research, Greenwich Biosciences</p> <p><i><b>SAGE 547 for status epilepticus</b></i> Jeffrey M. Jonas, MD, CEO and Director, Sage Therapeutics</p>
6:00 pm - 7:30 pm	<p><b>Poster Presentations</b> Chair: Kathleen Clarence-Smith, MD, PhD, Co-Founder, Partner, KM Pharmaceuticals</p>
6:00 pm - 7:30 pm	<p><b>Poster Reception: 20th Anniversary Celebration</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.</p> <p>All attendees invited to celebrate our 20th Anniversary Celebration.</p>



## Saturday, March 10, 2018

TIME	ACTIVITY
7:00 am - 7:30 am	<b>Breakfast</b>
7:45 am - 12:15pm	<b>Training in Neurotherapeutics: Closing Day</b> Chairs: Michael Rogawski, MD, PhD, Professor, Neurology, University of California, Davis Barbara Slusher, PhD, MAS, Professor of Neurology, Psychiatry, Neuroscience, Medicine, and Oncology, Johns Hopkins School of Medicine Karl Scheidt, Professor, Northwestern Medicine, Founder, Third Coast Therapeutics
7:30 am - 8:00 am	<b>ASENT Business Meeting</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc. <i>All members welcome to attend</i>
8:00 am - 10:00 am	<b>Symposium: Technology enabled measurements: Emerging role in Neurotherapeutics</b> Chair: William J. Marks, Jr., MD, MS, Head of Clinical Neurology, Verily Life Sciences  <b>Faculty</b> <b><i>Physiological biomarkers in the brain: Revelations from direct brain sensing in epilepsy</i></b> <i>Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.</i>  <b><i>Wearable technologies: Contributions to the treatment of movement disorders</i></b> <i>William J. Marks, Jr., MD, MS, Head of Clinical Neurology, Verily Life Sciences</i>  <b><i>App based systems to support neurotherapeutic development: a virtual clinical trial in Migraine</i></b> <i>Gabriel Vargas, MD, PhD, Executive Medical Director, Digital Health &amp; Neuroscience Therapeutic Area Head, Early Development, Amgen</i>  <b><i>Regulatory considerations for use of technology-derived data: the CDRH perspective</i></b> <i>Carlos Peña, PhD, Director, Division of Neurological and Physical Medicine Devices (DNPM), FDA</i>  <b><i>Moderated Discussion</i></b> <i>William J. Marks, Jr., MD, MS, Head of Clinical Neurology, Verily Life Sciences</i>
10:00 am - 10:15 am	Break
10:15 am - 12:15 pm	<b>Emerging Therapies: Parkinson's Disease</b> Chair: Michael Okun, MD, Administrative Director & Co-Director, Center for Movement Disorders and Neurorestoration, Center for Translational Research in Neurodegenerative Diseases, the McKnight Brain Institute, University of Florida College of Medicine  <b>Faculty</b> <b><i>Introduction</i></b> <i>Michael Okun, MD, Administrative Director &amp; Co-Director, Center for Movement Disorders and Neurorestoration, Center for Translational Research in Neurodegenerative Diseases, the McKnight Brain Institute, University of Florida College of Medicine</i>  <b><i>Current steering technologies</i></b> <i>Chris Butson, PhD, Associate Professor, Scientific Computing &amp; Imaging (SCI) Institute, Department of Bioengineering, University of Utah</i>  <b><i>Adaptive deep brain stimulation</i></b> <i>Timothy Denison, PhD, Vice President of Research and Core Technology, Medtronic</i>  <b><i>Repurposing Isradipine for neuroprotection in Parkinson's Disease</i></b> <i>Tanya Simuni, MD, Chief of Movement Disorders in the Department of Neurology, Northwestern University</i>  <b><i>Vaccines in Parkinson's Disease</i></b> <i>Malu Tansey, PhD, Associate Professor, Department of Physiology, Emory University</i>
12:15 pm - 1:30 pm	<b>Committee Meetings and Networking Meetings</b> Chair: Martha Morrell, MD, Chief Medical Officer, NeuroPace, Inc.

## Training in Neurotherapeutics: Discovery and Development for Academic Scientists

Wednesday, March 7 - Saturday, March 10

*Course is offered in partnership with ASENT and is supported by National Institute of Neurological Disorders and Stroke Grants 1R25NS077582 and 1R25NS099170. Participants must apply and be accepted in order to participate in the course.*

*The training program is affiliated with the Division of Translational Research of the National Institute of Neurological Disorders and Stroke and the Blueprint Neurotherapeutics Network of the NIH Blueprint for Neuroscience Research. Program Director: Dr. Charles Cywin.*

Wednesday, March 7, 2018		
7:45 am – 8:30 am	Check-in and Continental Breakfast	
8:30 am – 9:00 am	Overview: The Neurotherapeutics Discovery and Development Process	Michael A. Rogawski, MD, PhD, University of California, Davis
9:00 am – 9:50 am	Session 1: Target and Pathway Interrogation	James Inglese, PhD, National Center for Advancing Translational Sciences, NIH
9:50 am – 10:15 am	Break	
10:15 am – 11:05 am	Session 2: Biology Basics for Identifying Hits	William Janzen, BS, Epizyme, Inc.
11:05 am – 11:55 am	Session 3: Moving from Hit to Lead to Clinical Candidate	James Barrow, PhD, Johns Hopkins School of Medicine
11:55 am – 12:45 am	Session 4: Antibody-Based Therapies	Gai Ayalon, PhD, Genentech
12:45 pm – 1:55 pm	Lunch	Students paired with mentors
1:55 pm – 2:45 pm	Session 5: Assessing Unmet Needs and Advancing Early Stage Medical Innovations in Multiple Domains to Attract Resources and Progress to Clinical Impact	Steven Schachter, MD, Harvard Medical School
2:45 pm – 3:35 pm	Session 6: Intellectual Property	Jeffrey W. Childers, PhD, Michael Best & Friedrich LLP (formerly Johns Hopkins Technology Transfer)
3:35 pm – 3:55 pm	Break	
3:55 pm – 5:30 pm	Engagement Exercise 1: Clarify vision statement and begin to develop the components of presentation	
5:30 pm – 6:15 pm	Networking Reception	
6:15 pm – 8:15 pm	Dinner	

## Training in Neurotherapeutics: Discovery and Development for Academic Scientists

Wednesday, March 7 - Saturday, March 10

### Thursday, March 8, 2018

7:15 am – 8:00 am	Continental Breakfast	
8:00 am – 8:50 am	Session 7: Alternative Approaches to Lead Generation	Sam J. Enna, PhD, The University of Kansas
8:50 am – 9:40 am	Session 8: ADME	Kennan Marsh, PhD, AbbVie
9:40 am – 10:00 am	Break	
10:00 am – 10:50 am	Session 9: Preclinical Models of CNS Disease: Efficacy and Target Engagement	Matthew Kennedy, PhD, University of Colorado Denver
10:50 am – 12:30 pm	Session 10: Cell-Based Therapies	Steven A. Goldman, MD, PhD, University of Rochester Medical Center
		and University of Copenhagen
12:30 pm – 1:45 pm	Lunch	Responsible Conduct of Research Exercise
1:45 pm – 5:30 pm	ASENT Pipeline Presentations	
5:30 pm – 6:00 pm	Break	
6:00 pm – 8:30 pm	Course Dinner and After Dinner Talk	C. Frank Bennett, PhD, Ionis Pharmaceuticals, Inc.
	Development of SPINRAZA™ (nusinersen) for Spinal Muscular Atrophy	

### Friday, March 9, 2018

7:15 am – 8:00 am	Continental Breakfast	
8:00 am – 8:50 am	Lecture 11: Toxicology	Adaline Smith, PhD, DABT, Ironwood Pharmaceuticals
8:50 am – 9:40 am	Lecture 12: IND Enabling Studies and Preparation of the IND	William M. Bracken, AbbVie Research and Development
9:40 am – 10:00 am	Break	
10:00 am – 11:00 am	Lecture 13: Formulation and Route of Administration	James Cloyd III, PharmD, University of Minnesota
11:00 am – 10:20 am	Break	
11:20 am – 12:15 pm	Lecture 14: Gene-base Therapies	Michael G. Kaplitt, MD, PhD, Weill Cornell Medical College
12:15 pm – 1:30 pm	Lunch	
1:30 pm – 5:30 pm	Engagement Exercise 2: Round Robin	
5:45 pm – 8:30 pm	Course Dinner at Restaurant	

## Training in Neurotherapeutics: Discovery and Development for Academic Scientists

Wednesday, March 7 - Saturday, March 10

### Saturday, March 10, 2018

7:15 am – 8:00 am	Continental Breakfast	
8:00 – 8:30 am	Session 15: Rigor in Translational Drug Discovery and Development	Shai Silberberg, PhD, NIH/NINDS
8:30 am – 9:20 pm	Session 14: Funding Academic Drug Discovery Research	Charles L. Cywin, PhD, NIH/NINDS
9:20 am – 10:30 am	Engagement Exercise 3: Student Presentations	
10:30 am – 10:50 am	Break	
10:50 am – 12:00 am	Engagement Exercise 3: Student Presentations (continued)	
12:00 pm – 12:15 pm	Conclusion: Where do we go from here? Presentation of plan for continued mentoring, engagement and course evaluation over two-year period	Course Directors
12:15 pm	Adjourn	



# Save the Date

# March 7-10, 2018

## Hilton Rockville



### Location

The ASENT Annual Meeting will take place March 7-10, 2018 at the Hilton Washington DC/Rockville Hotel and Executive Meeting Center in Rockville, Maryland.

### Book your hotel room

Annual Meeting Rate: \$209 Single / Double, +tax

To reserve a room online, visit:

<http://bit.ly/2Ab26Hd>

**Hotel Deadline:** Monday, February 12, 2018.

A one-night, NON-refundable deposit representing the first night of your reservation will be charged by the hotel when you book your reservation.

### Early Bird Rate

Register online at [asent.org](http://asent.org) by January 18, 2018 in order to receive the early bird rates. After January 18, standard rates will apply. Once you have registered online, you will receive a confirmation email. If you do not receive a confirmation email [sandypizzoferrato.asent@gmail.org](mailto:sandypizzoferrato.asent@gmail.org).

### Abstract Submission Deadline

Abstracts will be accepted for review until January 29, 2018. To submit your abstract for review visit, [ASENT.org](http://ASENT.org).

### Poster Hours

Thursday, March 8, 3:45 pm – 5:30 pm

Friday, March 9, 4:15 pm – 6:00 pm

Poster presenters will be in attendance while posters are on view.

### Benefits of Membership

The American Society for Experimental Neurotherapeutics invites you to join this independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. To join today visit [ASENT.org](http://ASENT.org).

### Consent to use photographic images

Registration and attendance at, or participation in, ASENT meetings and other related activities constitutes attendee's authorization to ANA's use and distribution (both now and in the future) of the attendee's image or voice in photographs, video recordings, electronic reproductions, audio recordings, and other media throughout the world and royalty free.

### Cancellation Policy

To cancel your registration and receive a refund, a written request with your registration confirmation must be received by February 7, 2018. Please send your request to [sandypizzoferrato.asent@gmail.org](mailto:sandypizzoferrato.asent@gmail.org). Cancellation requests received by this date will receive a refund less a \$50 processing fee. Refunds will be

# ASENT 2018 Annual Meeting Registration

**Register online at <http://asent.org>**

**EARLY BIRD DEADLINE: January 18, 2018**

*Register before 1/18/18 to save \$100*

Registration Type	Pre-Meeting Only	Annual Meeting & Pre-Meeting Symposium	Annual Meeting Only	One Day
Non-Member	\$650	\$1,525	\$975	\$475
Regular Member	\$450	\$1,125	\$775	\$400
Trainee	\$250	\$625	\$475	\$275
Government	\$350	\$925	\$675	\$350
NonProfit / Advocacy	\$250	\$625	\$475	\$275

**Co-Chair**

C. Anthony Altar, PhD

**Co-Chair**

Bennett L, Lavenstein, MD

**Members**

Mitchell Brin  
Enrique Carrazana  
Amy Chappell  
Kathleen Clarence-Smith  
Robin Elliott  
Stewart Factor  
Howard Federoff  
Robert Hamill  
Korie Handwerger  
Dietrich Haubenberger  
Petra Kaufmann  
Victor Krauthamer  
Patrick Mabray  
Jill Rasmussen  
Steve Schachter  
Dwain Tolbert  
Marc Walton

**Ex-Officio**

Martha Morrell, MD

**Staff Contacts****Executive Director**

Jessica Keenan Smith  
[jessicasmith.asent@gmail.com](mailto:jessicasmith.asent@gmail.com)

**Director of Operations**

Sandy Pizzoferrato  
[sandypizzoferrato.asent@gmail.com](mailto:sandypizzoferrato.asent@gmail.com)

**Director of Development**

Terrie Blalock  
[tblalock1@nc.rr.com](mailto:tblalock1@nc.rr.com)

**Main Contact**

Phone: 833-273-6800  
Email: [jessicasmith.asent@gmail.com](mailto:jessicasmith.asent@gmail.com)

**Mail Address**

ASENT  
230 Kings Highway East  
Ste. 245  
Haddonfield, NJ 08033

# ASENT 2018 Board of Directors

Officers	
President Martha Morrell, MD NeuroPace, Inc <i>Chair, Development Committee</i>	President-Elect Thomas P. Sutula, MD, PhD University of Wisconsin - Madison
Secretary Robin A. Elliott, MA Parkinson's Disease Foundation & World Parkinson Congress (retired)	Treasurer Robert W. Hamill, MD University of Vermont College of Medicine, Department of Neurological Sciences
Immediate Past President Howard J. Federoff, MD, PhD University of California - Irvine	
Directors	
Amy S. Chappell, MD Naples, FL	Timothy Coetzee, PhD National Multiple Sclerosis
O'Neill D'Cruz, MD, MBA, FAAN OD Consulting and Neurological Services, PLLC <i>Co-Chair, Membership and Communications                      Committee</i>	Stewart A. Factor, DO Emory University School of Medicine <i>Co-Chair, ASENT Translational Research Course</i>
Toby Ferguson, MD, PhD Biogen Idec, Inc	Lynn D. Kramer, MD Eisai, Inc.
Victor Krauthamer, PhD Food and Drug Administration (retired)	Bennett L. Lavenstein, MD Children's Hospital Medical Center <i>Co-Chair, Program Committee</i>
Steven Schachter, MD CIMIT/Harvard Medical School	John R. Richert, MD Richert Partners
EX-OFFICIO	
Neurotherapeutics® Editor-in-Chief M. Maral Mouradian, MD Rutgers University	Program Committee Co-Chair C. Anthony Altar, PhD Verge Genomics
NIH Blueprint Course Liaison Barbara Slusher, PhD, MAS John Hopkins Brain Science Institute	Federal Liaison Amir Tamiz, PhD NIH, NINDS, OTR
David Shoup The Curry Rockefeller Group Co-Chair, Communications	





**American Society for Experimental Neurotherapeutics**

20th Annual Meeting | March 7-10, 2018 | Rockville, MD

**Register at [ASENT.ORG](http://ASENT.ORG)**

